7月20日，中国生物制药盘中上涨3.01%，报5.14港元/股，成交额6755.82万港元。制药板块集体走强，东阳光药涨5.29%，石药集团涨4.32%，恒瑞医药涨4.18%，凯莱英涨4.1%，翰森制药涨3.71%。
公司近期利好密集：7月14日旗下TRD205获CDE突破性治疗药物认定；7月10日IDH1抑制剂TQB3454上市申请获受理；7月8日与阿斯利康达成TQC3721海外独家授权协议，总对价最高达19亿美元，同日深化与GSK呼吸领域战略合作。多家券商维持买入评级，招银国际目标价8.70港元，交银国际目标价7.70港元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.